Physician profile
Catina E Painter
NPI 1558638056
$568.43
in general payments reported to CMS, 2019-2025
13 companies · $515 in 2025
The $515 reported for 2025 was more than what 77% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.70 · 2024: $34.53 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $181.25 | 2025 | |
| Janssen Biotech, INC. | $68.90 | 2025 | Erleada |
| Myriad Genetic Laboratories, INC. | $61.88 | 2024-2025 | Prolaris |
| Vertex Pharmaceuticals Incorporated | $42.36 | 2025 | |
| Blue Earth Diagnostics | $41.97 | 2025 | Posluma |
| Progenics Pharmaceuticals, INC. | $29.03 | 2025 | |
| Teleflex LLC | $24.61 | 2025 | Barrigel |
| Janssen Scientific Affairs, LLC | $22.45 | 2025 | |
| Medtronic, INC. | $20.23 | 2025 | Interstim |
| Dendreon Pharmaceuticals LLC | $20.22 | 2025 | Provenge |
| Telix Pharmaceuticals | $19.58 | 2025 | Illuccix |
| Incyte Corporation | $18.70 | 2023 | Jakafi |
| Boston Scientific Corporation | $17.25 | 2024 | Rezum Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catina Painter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.